Harvard Bioscience (HBIO) Non-Current Assets (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Non-Current Assets data on file, last reported at $30.5 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 12.72% year-over-year to $30.5 million in Q1 2026; TTM through Mar 2026 was $131.6 million, a 53.55% decrease from a year earlier, with the FY2025 full-year figure at $31.8 million, down 60.94% from the prior year.
• Non-Current Assets for Q1 2026 stood at $30.5 million, down from $31.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for HBIO reached as high as $98.8 million in Q2 2022 and fell as low as $30.5 million in Q1 2026.
• Historically, Non-Current Assets has averaged $73.4 million across 5 years, with a median of $85.0 million in 2024.
• Across the five-year window, Non-Current Assets decreased 1.63% in 2022 and slumped 60.94% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $94.2 million in 2022, then decreased by 6.27% to $88.3 million in 2023, then decreased by 7.7% to $81.5 million in 2024, then slumped by 60.94% to $31.8 million in 2025, then fell by 4.36% to $30.5 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $30.5 million in Q1 2026, $31.8 million in Q4 2025, and $34.2 million in Q3 2025.